Induced Pluripotent Stem Cells for Post–Myocardial Infarction Repair: Remarkable Opportunities and Challenges

• Published in: Circulation research Vol. 114; no. 8; pp. 1328 - 1345
• Main Authors: Lalit, Pratik A, Hei, Derek J, Raval, Amish N, Kamp, Timothy J
• Format: Journal Article
• Language: English
• Published: United States American Heart Association, Inc 11.04.2014
• Subjects: Animals; Cell Differentiation; Cell- and Tissue-Based Therapy - methods; Cellular Senescence; Disease Models, Animal; Heart Failure - pathology; Heart Failure - prevention & control; Humans; Mice; Myocardial Infarction - pathology; Myocardial Infarction - therapy; Pluripotent Stem Cells - cytology; Pluripotent Stem Cells - transplantation; Rats; Risk Factors; Stem Cell Transplantation - methods; Tissue Engineering - methods; Tissue Engineering - trends; cell- and tissue-based therapy; tissue engineering; induced pluripotent stem cell; regenerative medicine; myocardial infarction
• ISSN: 0009-7330; 1524-4571
• DOI: 10.1161/CIRCRESAHA.114.300556

Coronary artery disease with associated myocardial infarction continues to be a major cause of death and morbidity around the world, despite significant advances in therapy. Patients who have large myocardial infarctions are at highest risk for progressive heart failure and death, and cell-based therapies offer new hope for these patients. A recently discovered cell source for cardiac repair has emerged as a result of a breakthrough reprogramming somatic cells to induced pluripotent stem cells (iPSCs). The iPSCs can proliferate indefinitely in culture and can differentiate into cardiac lineages, including cardiomyocytes, smooth muscle cells, endothelial cells, and cardiac progenitors. Thus, large quantities of desired cell products can be generated without being limited by cellular senescence. The iPSCs can be obtained from patients to allow autologous therapy or, alternatively, banks of human leukocyte antigen diverse iPSCs are possible for allogeneic therapy. Preclinical animal studies using a variety of cell preparations generated from iPSCs have shown evidence of cardiac repair. Methodology for the production of clinical grade products from human iPSCs is in place. Ongoing studies for the safety of various iPSC preparations with regard to the risk of tumor formation, immune rejection, induction of arrhythmias, and formation of stable cardiac grafts are needed as the field advances toward the first-in-man trials of iPSCs after myocardial infarction.